Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT06153420 is registered in ClinicalTrials.gov with CinPhloro Pharma, LLC as lead sponsor.

NCT NCT06153420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06153420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
Lead sponsor
CinPhloro Pharma, LLC
Phase
Phase 2
Overall status
Terminated
Start date
December 28, 2023
Completion date
July 28, 2025
Enrollment
421 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea